trending Market Intelligence /marketintelligence/en/news-insights/trending/CMsfuVRoP7d98Uro-oSK1Q2 content esgSubNav
In This List

Fresenius' dialysis system receives US FDA breakthrough-device tag

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Fresenius' dialysis system receives US FDA breakthrough-device tag

Fresenius Medical Care AG & Co. KGaA's dialysis system that prevents blood clotting without the use of blood-thinning drugs has received the U.S. Food and Drug Administration's breakthrough-device designation.

The dialysis system is manufactured using Endexo, a polymer that inhibits adhesion of proteins and platelets to the device surface and reduces clot risk. The system also uses Citrasate as a dialysate, a solution of pure water, electrolytes and salts that pulls toxins from the blood.

Fresenius' unit Fresenius Medical Care North America Holdings LP acquired an exclusive worldwide license from Interface Biologics Inc. to use Endexo technology to manufacture various components of its dialysis system.

The U.S. regulator granted breakthrough device designation to Fresenius' computer-assisted ultrafiltration control software in March.

The breakthrough designation speeds up the development and review process for technologies that provide more effective treatment or diagnosis of life-threatening or debilitating diseases.